Jon P. Stonehouse

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) were trading lower by more than 65 percent early Monday morning after the company reported disappointing results from a clinical trial. BioCryst designs, optimizes and develops novel small molecule drugs that block key enzymes involved in...